MSD Animal Health has secured European Commission approval for Porcilis PCV M Hyo, presented by the company as Europe’s first single-shot vaccine for protecting piglets against both Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae.
“PCV2 and M. hyopneumoniae are two of the most important contributors to respiratory diseases in pigs and are a considerable burden for producers,” said MSD’s Narciso Bento, adding that the newly approved vaccine is a “convenient new option” and that it “provides the immunity piglets need during a crucial time in their development”.
The company said that using the product would reduce the total number of vaccinations given to young piglets, while providing protection against both diseases for at least 21 weeks. This would be after a single injection with no restrictions to maternally derived antibody levels.
Stating that the new single-injection advance was a technical breakthrough, MSD’s Ruud Segers said the new vaccine “delivers a favourable safety profile while retaining strong efficacy against both pathogens, providing protection for piglets and assurance for farmers”.